Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

ConditionLiver

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorM.D. Anderson Cancer Center

About this trial

To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below)

No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results)

No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection

Ability to stay within 50 miles of medical center for immediate postop period

Disqualifiers

Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy

Tumors not amenable to MIS or Robotic-assisted surgical resection

Evidence of Cirrhosis on imaging, clinically, or lab testing

Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period

Trial design

Design model

Single group

Treatments tested in this trial

Questionnaires
Behavioral
Survey

Treatment groups

36 Participants

are divided into 2 treatment groups

Group A: Accelerated Recovery ProtocolExperimental treatment 1 intervention

Group B: Comparison/Control ArmExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Time frame

through study completion; an average of 1 year.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

M.D. Anderson Cancer Center

Lead sponsor

Intuitive Surgical

Collaborator

Source ClinicalTrials.gov

Apply now